title: High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
authors.affiliation: Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan; Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Tokyo 142-8555, Japan. Electronic address: k.fujita@med.showa-u.ac.jp.
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Fujita
authors.affiliation: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan; Department of Respirology, National Hospital Organization, Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Hirose
authors.affiliation: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan.
authors.forename: Sojiro
authors.initials: S
authors.lastname: Kusumoto
authors.affiliation: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan.
authors.forename: Tomohide
authors.initials: T
authors.lastname: Sugiyama
authors.affiliation: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan.
authors.forename: Takao
authors.initials: T
authors.lastname: Shirai
authors.affiliation: Division of Respiratory Medicine and Allergology, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan.
authors.forename: Masanao
authors.initials: M
authors.lastname: Nakashima
authors.affiliation: Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Akiyama
authors.affiliation: Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan; Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Tokyo 142-8555, Japan; Department of Medical Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo 142-8666, Japan.
authors.forename: Yasutsuna
authors.initials: Y
authors.lastname: Sasaki
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy; D000069347:Erlotinib Hydrochloride; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride
keywords: ABCG2; Erlotinib; High exposure; Interstitial lung disease; Pharmacokinetics; Polymorphism